← All trials
NCT05438394
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 13, 2022
- Primary completion
- Jan 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jun 30, 2022
- Last posted
- Nov 15, 2022
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peking UniversityLead sponsor
- CASI Pharmaceuticals, Inc.Collaborator
- Peking UniversityOverall official - principal investigator
- Peking UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.